Charles Schwab Investment Management Inc Vaxcyte, Inc. Transaction History
Charles Schwab Investment Management Inc
- $515 Billion
- Q3 2024
A detailed history of Charles Schwab Investment Management Inc transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 1,295,837 shares of PCVX stock, worth $119 Million. This represents 0.03% of its overall portfolio holdings.
Number of Shares
1,295,837
Previous 876,237
47.89%
Holding current value
$119 Million
Previous $66.2 Million
123.6%
% of portfolio
0.03%
Previous 0.01%
Shares
17 transactions
Others Institutions Holding PCVX
# of Institutions
354Shares Held
122MCall Options Held
775KPut Options Held
433K-
Vanguard Group Inc Valley Forge, PA11.4MShares$1.05 Billion0.02% of portfolio
-
Janus Henderson Group PLC London, X010.9MShares$1 Billion0.67% of portfolio
-
Black Rock Inc. New York, NY9.94MShares$910 Million0.02% of portfolio
-
Ra Capital Management, L.P. Boston, MA8.69MShares$796 Million13.83% of portfolio
-
Capital Research Global Investors Los Angeles, CA4.9MShares$449 Million0.12% of portfolio
About Vaxcyte, Inc.
- Ticker PCVX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,315,100
- Market Cap $5.43B
- Description
- Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...